Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

PFKFB2 Promoter Hypomethylation as Recurrence Predictive Marker in Well-Differentiated Thyroid Carcinomas

Full text
Barros-Filho, Mateus Camargo [1] ; Menezes de Lima, Larissa Barreto [1] ; dos Reis, Mariana Bisarro [1] ; Homem de Mello, Julia Bette [1] ; Beltrami, Caroline Moraes [1] ; Lopes Pinto, Clovis Antonio [2] ; Kowalski, Luiz Paulo [3] ; Rogatto, Silvia Regina [4]
Total Authors: 8
[1] AC Camargo Canc Ctr, Int Res Ctr CIPE, BR-01508010 Sao Paulo - Brazil
[2] AC Camargo Canc Ctr, Dept Pathol, BR-01509900 Sao Paulo - Brazil
[3] AC Camargo Canc Ctr, Dept Head & Neck Surg & Otorhinolaryngol, BR-01509900 Sao Paulo - Brazil
[4] Univ Southern Denmark, Dept Clin Genet, Vejle Hosp, Inst Reg Hlth Res, DK-7100 Vejle - Denmark
Total Affiliations: 4
Document type: Journal article
Web of Science Citations: 3

Despite the low mortality rates, well-differentiated thyroid carcinomas (WDTC) frequently relapse. BRAF and TERT mutations have been extensively related to prognosis in thyroid cancer. In this study, the methylation levels of selected CpGs (5-cytosine-phosphate-guanine-3) comprising a classifier, previously reported by our group, were assessed in combination with BRAF and TERT mutations. We evaluated 121 WDTC, three poorly-differentiated/anaplastic thyroid carcinomas (PDTC/ATC), 22 benign thyroid lesions (BTL), and 13 non-neoplastic thyroid (NT) tissues. BRAF (V600E) and TERT promoter (C228T and C250T) mutations were tested by pyrosequencing and Sanger sequencing, respectively. Three CpGs mapped in PFKFB2, ATP6V0C, and CXXC5 were evaluated by bisulfite pyrosequencing. ATP6V0C hypermethylation and PFKFB2 hypomethylation were detected in poor-prognosis (PDTC/ATC and relapsed WDTC) compared with good-prognosis (no relapsed WDTC) and non-malignant cases (NT/BTL). CXXC5 was hypomethylated in both poor and good-prognosis cases. Shorter disease-free survival was observed in WDTC patients presenting lower PFKFB2 methylation levels (p = 0.004). No association was observed on comparing BRAF (60.7%) and TERT (3.4%) mutations and prognosis. Lower PFKFB2 methylation levels was an independent factor of high relapse risk (Hazard Ratio = 3.2; CI95% = 1.1-9.5). PFKFB2 promoter methylation analysis has potential applicability to better stratify WDTC patients according to the recurrence risk, independently of BRAF and TERT mutations. (AU)

FAPESP's process: 15/20748-5 - Diagnostic and prognostic markers useful in the clinical practice for patients with thyroid nodules: validation of previous findings and functional studies
Grantee:Silvia Regina Rogatto
Support type: Regular Research Grants
FAPESP's process: 15/17707-5 - Development of molecular procedures useful for differential diagnosis in thyroid nodules
Grantee:Mateus de Camargo Barros Filho
Support type: Scholarships in Brazil - Post-Doctorate